AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14579082 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic strategy based on pretest probability and perfusion lung scan results
Number of subjects: 390
Study 10858683 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Alvarado score combined with selective laparoscopy
Number of subjects: 84
Study 10858683 — intervention group
Group type: COMPARATOR
Intervention: Control group (other surgical teams)
Number of subjects: 84
Study 9350066 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg pamidronate
Number of subjects: 60
Study 9350066 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 9350066 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg pamidronate
Number of subjects: 60
Study 7987528 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic waveform
Number of subjects: 79
Study 7987528 — intervention group
Group type: COMPARATOR
Intervention: Monophasic waveform
Number of subjects: 79
Study 2722900 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketanserin 40 mg twice daily for 3 days
Number of subjects: 8
Study 780041 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 650 mg
Number of subjects: 288
Study 780041 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen 600 mg
Number of subjects: 288
Study 780041 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 30 mg
Number of subjects: 288
Study 780041 — intervention group
Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 288
Study 780041 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 288
Study 30351511 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral methylprednisolone 1250 mg/day for 3 days
Number of subjects: 49
Study 30351511 — intervention group
Group type: COMPARATOR
Intervention: Oral methylprednisolone 625 mg/day for 3 days
Number of subjects: 49
Study 30351511 — intervention group
Group type: EXPERIMENTAL
Intervention: Both doses
Number of subjects: 49
Study 28598202 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral dose of amlodipine administered in the evening
Number of subjects: 0
Study 28598202 — intervention group
Group type: COMPARATOR
Intervention: Single oral dose of amlodipine administered in the morning
Number of subjects: 0
Study 26103668 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative-pressure septal drainage
Number of subjects: 60
Study 26103668 — intervention group
Group type: COMPARATOR
Intervention: Anterior nasal packs
Number of subjects: 60
Study 22645252 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa
Number of subjects: 0
Study 22645252 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 0
Study 22645252 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 21609410 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal glyceryl trinitrate (5 mg daily)
Number of subjects: 107
Study 21609410 — intervention group
Group type: COMPARATOR
Intervention: Placebo/control
Number of subjects: 107
Study 19226203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan
Number of subjects: 1002
Study 19226203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ertapenem
Number of subjects: 1002
Study 16871477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (0.05 mg/kg/day)
Number of subjects: 40
Study 16871477 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16871477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine (after 6 months monitoring)
Number of subjects: 40
Study 16871477 — intervention group
Group type: EXPERIMENTAL
Intervention: Tizanidine
Number of subjects: 40
Study 15027185 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG-PSN local injection following CO2 laser resection
Number of subjects: 106
Study 15027185 — intervention group
Group type: COMPARATOR
Intervention: Interferon subcutaneous injection following CO2 laser resection
Number of subjects: 106
Study 11576768 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifampicin (RIF) 450 mg capsule
Number of subjects: 6
Study 11576768 — intervention group
Group type: COMPARATOR
Intervention: Rifampicin‐isoniazid (RIF‐INH) 450+300 mg FDC capsule
Number of subjects: 6
Study 7551769 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 week training programme
Number of subjects: 60
Study 7551769 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 60
Study 7551769 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal exercise testing
Number of subjects: 60
Study 2030925 — intervention group
Group type: EXPERIMENTAL
Intervention: Large doses of enteric coated (EC) pancreatic enzymes (patient's usual dose)
Number of subjects: 9
Study 2030925 — intervention group
Group type: COMPARATOR
Intervention: Small doses of enteric coated (EC) pancreatic enzymes (1/4 usual dose)
Number of subjects: 9
Study 7093115 — intervention group
Group type: EXPERIMENTAL
Intervention: Single morning dose of methyldopa
Number of subjects: 10
Study 7093115 — intervention group
Group type: EXPERIMENTAL
Intervention: Single evening dose of methyldopa
Number of subjects: 10
Study 7093115 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 31494596 — intervention group
Group type: EXPERIMENTAL
Intervention: Live‐CCD
Number of subjects: 106
Study 31494596 — intervention group
Group type: EXPERIMENTAL
Intervention: Video‐CCD
Number of subjects: 106
Study 31494596 — intervention group
Group type: COMPARATOR
Intervention: Paper‐Cases
Number of subjects: 106
Study 28035477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM) used to identify the EBSLN during surgery
Number of subjects: 133
Study 28035477 — intervention group
Group type: COMPARATOR
Intervention: No attempt to identify the EBSLN
Number of subjects: 133
Study 28035477 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative neuromonitoring (IONM)
Number of subjects: 133
Study 26049549 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictive low-glucose suspend (PLGS) system active
Number of subjects: 81
Study 26049549 — intervention group
Group type: COMPARATOR
Intervention: Control (PLGS system inactive)
Number of subjects: 81
Study 23618821 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Lifestyle Modification Program
Number of subjects: 160
Study 23618821 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 160
Study 21890134 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF with elective single embryo transfer (IVF‐eSET)
Number of subjects: 116
Study 21890134 — intervention group
Group type: COMPARATOR
Intervention: IUI with controlled ovarian stimulation (IUI‐COS)
Number of subjects: 116
Study 19344622 — intervention group
Group type: EXPERIMENTAL
Intervention: Wet graft
Number of subjects: 384
Study 19344622 — intervention group
Group type: COMPARATOR
Intervention: Dry graft
Number of subjects: 384
Study 16581077 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding Journal intervention
Number of subjects: 303
Study 16581077 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 303
Study 14767255 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive recovery
Number of subjects: 12
Study 14767255 — intervention group
Group type: COMPARATOR
Intervention: Active recovery
Number of subjects: 12
Study 11465438 — intervention group
Group type: EXPERIMENTAL
Intervention: PDS foil (0.15 mm)
Number of subjects: 28
Study 11465438 — intervention group
Group type: COMPARATOR
Intervention: Titanium dynamic mesh (0.3 mm)
Number of subjects: 28
Study 9714694 — intervention group
Group type: EXPERIMENTAL
Intervention: PMA-stimulated conditions
Number of subjects: 15
Study 9714694 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonstimulated conditions
Number of subjects: 15
Study 9714694 — intervention group
Group type: EXPERIMENTAL
Intervention: RT-PCR analysis
Number of subjects: 15
Study 10449266 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal 5-fluorouracil (5-FU) cream
Number of subjects: 40
Study 10449266 — intervention group
Group type: COMPARATOR
Intervention: Intravaginal placebo cream
Number of subjects: 40
Study 2468964 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC, 2,400 mg X 2) + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Number of subjects: 10
Study 2468964 — intervention group
Group type: COMPARATOR
Intervention: Placebo + isosorbide-5-mononitrate (5-ISMN, 60 mg)
Number of subjects: 10
Study 334605 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibicorten
Number of subjects: 0
Study 334605 — intervention group
Group type: COMPARATOR
Intervention: Betamethasone valerate
Number of subjects: 0
Study 31794478 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibial cortex transverse distraction
Number of subjects: 136
Study 31794478 — intervention group
Group type: COMPARATOR
Intervention: Standard surgical treatment (control)
Number of subjects: 136
Study 31039208 — intervention group
Group type: EXPERIMENTAL
Intervention: Studied further from preferred time of day
Number of subjects: 100
Study 31039208 — intervention group
Group type: COMPARATOR
Intervention: Subjective sleepiness
Number of subjects: 100
Study 31039208 — intervention group
Group type: COMPARATOR
Intervention: Ambient illumination
Number of subjects: 100
Study 29040598 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 1 g twice a day)
Number of subjects: 90
Study 29040598 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 25979364 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 120
Study 25979364 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle and medical management
Number of subjects: 120
Study 23173821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter)
Number of subjects: 248
Study 23173821 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (160/80 mg, week 0/2; 40 mg, every other week thereafter) in patients using corticosteroids at baseline (N=90)
Number of subjects: 248
Study 22134266 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified cemented prosthesis
Number of subjects: 5
Study 22134266 — intervention group
Group type: COMPARATOR
Intervention: Conventional cemented prosthesis
Number of subjects: 5
Study 19833477 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiprofessional palliative care team (PCT) fast track
Number of subjects: 52
Study 19833477 — intervention group
Group type: COMPARATOR
Intervention: Control care group (best usual care)
Number of subjects: 52
Study 16902069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperoxia (mean end‐tidal O(2) 79.6 +/‐ 2.0%)
Number of subjects: 8
Study 16902069 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoxia (pulse oximeter oxygen saturation 82.6 +/‐ 0.3%)
Number of subjects: 8
Study 14747646 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-blame condition (N = 31)
Number of subjects: 49
Study 14747646 — intervention group
Group type: COMPARATOR
Intervention: Control condition (N = 18)
Number of subjects: 49
Study 11505349 — intervention group
Group type: EXPERIMENTAL
Intervention: 17beta-estradiol, 2mg, given orally twice in 14 hours before the operation
Number of subjects: 21
Study 9305559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion at 6.0 +/- 0.4 micrograms.kg-1.min-1 in young adults
Number of subjects: 51
Study 9305559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion at 4.3 +/- 0.3 micrograms.kg-1.min-1 in elderly patients
Number of subjects: 51
Study 9305559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion in patients with low plasma cholinesterase activity
Number of subjects: 51
Study 9305559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion titrated to maintain 95 +/- 4% twitch depression
Number of subjects: 51
Study 9305559 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium infusion with or without antagonism
Number of subjects: 51
Study 8280653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MAP) 1g/day i.m. 5 days/week for 4 weeks and then 500 mg twice a week
Number of subjects: 119
Study 8280653 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM) 20 mg/day orally
Number of subjects: 119
Study 8280653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate (MAP)
Number of subjects: 119
Study 8280653 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen (TAM)
Number of subjects: 119
Study 3531560 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 0
Study 3531560 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 0
Study 28693969 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity in an aquatic environment
Number of subjects: 140
Study 28693969 — intervention group
Group type: COMPARATOR
Intervention: Control Group (no specified intervention)
Number of subjects: 140
Study 27103382 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant users (n=32)
Number of subjects: 624
Study 27103382 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline anticoagulant use
Number of subjects: 624
Study 27103382 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant use at any time during the study
Number of subjects: 624
Study 27103382 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (n=624)
Number of subjects: 624
Study 23931150 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosal graft urethroplasty
Number of subjects: 47
Study 23931150 — intervention group
Group type: COMPARATOR
Intervention: Dorsal inlay buccal mucosal graft urethroplasty
Number of subjects: 47
Study 21733268 — intervention group
Group type: EXPERIMENTAL
Intervention: Energizer led through-school programme
Number of subjects: 1348
Study 21733268 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1348
Study 19887824 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated Peritoneal Dialysis (APD)
Number of subjects: 36
Study 19887824 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemodialysis (HD)
Number of subjects: 36
Study 19887824 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study 17351767 — intervention group
Group type: EXPERIMENTAL
Intervention: GABAB receptor agonist baclofen
Number of subjects: 0
Study 17351767 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study 15133591 — intervention group
Group type: EXPERIMENTAL
Intervention: COAST (Croydon Outreach and Assertive Support Team)
Number of subjects: 59
Study 15133591 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 59
Study 11428734 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide Turbuhaler (400 microg, once daily)
Number of subjects: 177
Study 11428734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 177
Study 9543172 — intervention group
Group type: EXPERIMENTAL
Intervention: men1 gene screening in 45 sporadic anterior pituitary tumors
Number of subjects: 45
Study 9543172 — intervention group
Group type: EXPERIMENTAL
Intervention: men1 gene expression analysis
Number of subjects: 45
Study 9543172 — intervention group
Group type: EXPERIMENTAL
Intervention: loss of heterozygosity (LOH) analysis
Number of subjects: 45
Study 9543172 — intervention group
Group type: EXPERIMENTAL
Intervention: intragenic polymorphism analysis
Number of subjects: 45
Study 9543172 — intervention group
Group type: EXPERIMENTAL
Intervention: overall conclusion
Number of subjects: 45
Study 7906757 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticoagulant treatment (nicoumalone or phenprocoumon)
Number of subjects: 3404
Study 7906757 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 3404
Study 2454254 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional intervention (weight loss, moderate sodium restriction, reduction of alcohol intake)
Number of subjects: 167
Study 6179410 — intervention group
Group type: EXPERIMENTAL
Intervention: High-protein supplements
Number of subjects: 0
Study 6179410 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced protein-calorie supplements
Number of subjects: 0
Study 6179410 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional treatment
Number of subjects: 0
Study 31282418 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness Based Stress Reduction (MBSR)
Number of subjects: 14
Study 31282418 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 14
Study 27598906 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed palatal crib
Number of subjects: 41
Study 27598906 — intervention group
Group type: COMPARATOR
Intervention: Removable palatal crib
Number of subjects: 41
Study 25463693 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumatic Compression Device (PCD)
Number of subjects: 10
Study 25463693 — intervention group
Group type: COMPARATOR
Intervention: Passive Recovery (PR)
Number of subjects: 10
Study 24387886 — intervention group
Group type: EXPERIMENTAL
Intervention: HVLA manipulation
Number of subjects: 22
Study 24387886 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 22
Study 22945298 — intervention group
Group type: EXPERIMENTAL
Intervention: rhIGF1 (15 μg/kg per day for 1 month and 30 μg/kg per day for 5 months)
Number of subjects: 14
Study 22945298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 19294960 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory stimulation during REM sleep (below-waking threshold tone presentations)
Number of subjects: 35
Study 19294960 — intervention group
Group type: COMPARATOR
Intervention: Control REM sleep conditions without tone presentations
Number of subjects: 35
Study 17442687 — intervention group
Group type: EXPERIMENTAL
Intervention: Etoricoxib (120 mg)
Number of subjects: 0
Study 17442687 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 0
Study 15077073 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugate vaccine
Number of subjects: 83
Study 12585000 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate aqueous nasal spray (400 micrograms daily for 6 weeks for isolated rhinitis and 6 months for associated forms)
Number of subjects: 88
Study 12585000 — intervention group
Group type: COMPARATOR
Intervention: Control group (no therapy)
Number of subjects: 88
Study 9519052 — intervention group
Group type: EXPERIMENTAL
Intervention: CT with 1 mm collimation and pitch 2.0
Number of subjects: 40
Study 9519052 — intervention group
Group type: COMPARATOR
Intervention: CT with 1 mm collimation and pitch 1.0
Number of subjects: 40
Study 9519052 — intervention group
Group type: COMPARATOR
Intervention: CT with collimation of 3 mm or higher
Number of subjects: 40
Study 7978005 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients (symptomatic)
Number of subjects: 16
Study 7978005 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients (asymptomatic)
Number of subjects: 16
Study 7978005 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (normals)
Number of subjects: 16
Study 7978005 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic postcholecystectomy patients
Number of subjects: 16
Study 7978005 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic postcholecystectomy patients
Number of subjects: 16
Study 7978005 — intervention group
Group type: EXPERIMENTAL
Intervention: Postcholecystectomy patients
Number of subjects: 16
Study 2563741 — intervention group
Group type: EXPERIMENTAL
Intervention: Single photon emission computed tomography (SPECT)
Number of subjects: 135
Study 2563741 — intervention group
Group type: COMPARATOR
Intervention: Planar imaging
Number of subjects: 135
Study 787958 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 mg per day)
Number of subjects: 30
Study 787958 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 30769263 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (CBT/Integrated) - 15 individual sessions including motivational therapy, coping skills training, relapse prevention for SUD, and ADHD skills training
Number of subjects: 119
Study 30769263 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD) - 10 individual SUD treatment sessions
Number of subjects: 119
Study 30769263 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Cognitive Behavioral Therapy (CBT/Integrated)
Number of subjects: 119
Study 30769263 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy directed at SUD only (CBT/SUD)
Number of subjects: 119
Study 28542447 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg/day)
Number of subjects: 44
Study 28542447 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 25939711 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g metformin twice daily
Number of subjects: 34
Study 24152839 — intervention group
Group type: EXPERIMENTAL
Intervention: Berberis aristata/Silybum marianum
Number of subjects: 105
Study 24152839 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105
Study 21737373 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of rhLFA3‐IgFP (15 mg/week)
Number of subjects: 212
Study 21737373 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral administration of blank dummy methotrexate (7.5 mg/week)
Number of subjects: 212
Study 21737373 — intervention group
Group type: COMPARATOR
Intervention: Control group received oral methotrexate (7.5 mg/week) and intramuscular injection of blank dummy rhLFA3‐IgFP (15 mg/week)
Number of subjects: 212
Study 19335890 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary lifestyle intervention including physical activity lessons, nutrition education, and reduced media use over one school year.
Number of subjects: 40
Study 19335890 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 40
Study 17521477 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with TBI
Number of subjects: 0
Study 17521477 — intervention group
Group type: COMPARATOR
Intervention: Significant Others (SO)
Number of subjects: 0
Study 15456674 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress Management Training (SMT)
Number of subjects: 44